Fulgent Genetics, Inc. - Common Stock (FLGT)

Fulgent Genetics (NASDAQ:FLGT) reported second-quarter 2026 revenue of $85.4 million, up 20% sequentially and 4% from a year earlier, as the company incorporated a full quarter of contributions from Bako Diagnostics and StrataDx. Management also lowered its full-year revenue outlook, citing lower co

Fulgent (FLGT) Q1 2026 Earnings Transcript

Fulgent Genetics (FLGT) Earnings Transcript

Fulgent Genetics (FLGT) Earnings Call Transcript

Fulgent Genetics Q3 2025 earnings beat expectations with a surprise profit, causing a 4% pre-market stock surge. The company also raised its full-year guidance.

Fulgent Genetics has seen its fortunes shift since the pandemic. Is it a solid investment or a risky bet? Join us as we break down its performance and management decisions.

The next-generation diagnostics specialist had a beat-and-raise second quarter.

As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Fulgent Genetics exceeded expectations in the fourth quarter of 2024, showcasing robust revenue growth and a GAAP loss.